Court of Chancery of Delaware October 12, 2020, C.A. No. 2017-0863-KSJM (Shareholder Representative Services LLC v. Shire US Holdings, Inc.)

Also known as

United States · · · 12-10-2020

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE

SHAREHOLDER REPRESENTATIVE )

SERVICES LLC, in its capacity as the )

Equityholders’ Representative for the )

former stockholders of FerroKin )

Biosciences, Inc., )

)

Plaintiff, )

)

v. ) C.A. No. 2017-0863-KSJM

)

SHIRE US HOLDINGS, INC. and )

SHIRE PHARMACEUTICALS LLC, )

)

Defendants. )

MEMORANDUM OPINION

Date Submitted: July 31, 2020

Date Decided: October 12, 2020

Bradley R. Aronstam, Adam D. Gold, Roger S. Stronach, ROSS ARONSTAM &

MORITZ LLP, Wilmington, Delaware; Stuart L. Gasner, Laurie Carr Mims,

Jennifer A. Huber, Bailey W. Heaps, Christina Lee, KEKER, VAN NEST &

PETERS LLP, San Francisco, California; Counsel for Plaintiff Shareholder

Representative Services LLC.

Peter B. Ladig, Emily A. Letcher, BAYARD, P.A., Wilmington, Delaware; Timothy

W. Mungovan, Colin G. Cabral, Michael R. Hackett, James R. Anderson, Alexandra

Bargoot, PROSKAUER ROSE LLP, Boston, Massachusetts; Counsel for

Defendants Shire US Holdings, Inc. and Shire Pharmaceuticals LLC.

McCORMICK, V.C.

This case arises from a merger agreement executed in 2012 under which

Defendant Shire Pharmaceuticals LLC (“Shire”) acquired FerroKin BioSciences,

Inc. (“FerroKin”) and its experimental iron chelation drug, deferitazole. The merger

agreement required Shire to make a $45 million milestone payment to former

FerroKin equityholders upon the initiation of Phase III clinical trials. It further

deemed the relevant milestone achieved as of December 31, 2015, regardless of

whether Phase III clinical trials had actually been initiated by that date. The merger

agreement terminated Shire’s obligation to make the milestone payment if its failure

to initiate Phase III clinical trials was “as a result of a Fundamental Circumstance,”

defined as a circumstance in which material safety or efficacy concerns made it

impracticable to produce and sell or to obtain regulatory approval for deferitazole.

Read the full text

This document is published by courtlistener.com.

Moonlit adds the citation network, article-level links and cross-references, which are available to search for free.